Albany Molecular Research Company Profile (NASDAQ:AMRI)

About Albany Molecular Research

Albany Molecular Research, Inc. is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM). The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small-scale commercial manufacturing. API includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates and high potency and controlled substance manufacturing. DPM includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized injectable formulations. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: AMRI
CUSIP:

Key Metrics:

Previous Close: $16.28
50 Day Moving Average: $15.11
200 Day Moving Average: $14.67
52-Week Range: $12.45 - $20.65
Trailing P/E Ratio: N/A
Foreward P/E Ratio: 12.23
P/E Growth: 1.33
Market Cap: $574.22M
Outstanding Shares: 34,529,000
Beta: 1.4

Profitability:

Net Margins: -7.37%
Return on Equity: 3.17%
Return on Assets: 1.07%

Debt:

Debt-to-Equity Ratio: 1.41%
Current Ratio: 2.50%
Quick Ratio: 1.59%

Additional Links:

Companies Related to Albany Molecular Research:

Consensus Ratings for Albany Molecular Research (NASDAQ:AMRI) (?)

Ratings Breakdown:	2 Buy Ratings
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$21.00 (27.20% upside)

Analysts' Ratings History for Albany Molecular Research (NASDAQ:AMRI)

Show:

Date	Firm	Action	Rating	Price Target
8/5/2016	Morgan Stanley	Reiterated Rating	Buy	$17.00
10/26/2015	First Analysis	Upgrade	Equal Weight -> Overweight	$25.00
11/6/2014	JPMorgan Chase & Co.	Reiterated Rating	Overweight	$25.00 -> $22.00

(Data available from 10/1/2014 forward)

Earnings History for Albany Molecular Research (NASDAQ:AMRI)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/3/2016
8/4/2016	Q216	$0.32	$0.36	$123.10 million	$116.50 million	View	Listen
5/10/2016	Q1	$0.21	$0.07	$107.20 million	$102.80 million	View	Listen
2/17/2016	Q415	$0.36	$0.40	$133.40 million	$126.40 million	View	Listen
11/5/2015	Q315	$0.11	$0.11	$95.15 million	$101.40 million	View	Listen
8/4/2015	Q215	$0.18	$0.22	$85.00 million	$85.20 million	View	Listen
5/5/2015	Q115	$0.15	$0.20	$81.50 million	$75.10 million	View	N/A
2/12/2015	Q414	$0.33	$0.28	$91.90 million	$86.60 million	View	N/A
11/5/2014		$0.16	($0.02)			View	N/A
8/5/2014	Q214	$0.20	$0.22	$65.64 million	$68.20 million	View	N/A
5/6/2014	Q114	$0.23	$0.16	$62.19 million	$51.00 million	View	N/A
2/12/2014	Q4	$0.17	$0.22			View	N/A
11/6/2013	Q313	$0.11	$0.13	$62.10 million	$53.00 million	View	N/A
8/6/2013	Q2 2013		$0.12	$50.00 million	$59.30 million	View	N/A
5/7/2013	Q1 2013	$0.10	$0.23	$53.70 million	$59.40 million	View	N/A
2/12/2013	Q4 2012	$0.09	$0.17	$56.49 million	$59.10 million	View	N/A
8/1/2012		$0.02	$0.01			View	N/A
5/9/2012		$0.05	$0.02			View	N/A
2/7/2012		($0.12)	($0.19)			View	N/A
11/8/2011		($0.05)	($0.19)			View	N/A
8/8/2011		($0.03)	($0.02)			View	N/A
5/4/2011		($0.14)	($0.02)			View	N/A
2/7/2011		($0.15)	($0.16)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Albany Molecular Research (NASDAQ:AMRI)

Current Year EPS Consensus Estimate: $0.98 EPS
Next Year EPS Consensus Estimate: $1.35 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q2 2016	1	$0.33	$0.33	$0.33
Q3 2016	1	$0.13	$0.13	$0.13
Q4 2016	1	$0.52	$0.52	$0.52
Q1 2017	1	$0.20	$0.20	$0.20
Q2 2017	1	$0.34	$0.34	$0.34

(Data provided by Zacks Investment Research)

Dividend History for Albany Molecular Research (NASDAQ:AMRI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Albany Molecular Research (NASDAQ:AMRI)

Insider Ownership Percentage: 17.50%
Institutional Ownership Percentage: 71.39%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
8/9/2016	Steven R Hagen	SVP	Sell	1,401	$15.29	$21,421.29
5/31/2016	Kevin Oconnor	Director	Sell	5,000	$14.41	$72,050.00
5/16/2016	William S Marth	CEO	Buy	12,500	$12.86	$160,750.00
5/13/2016	George Svokos	COO	Buy	12,500	$12.82	$160,250.00
5/13/2016	Steven R Hagen	SVP	Sell	2,361	$12.77	$30,149.97
11/9/2015	Ambra Constance M D	Major Shareholder	Sell	50,000	$19.60	$980,000.00
8/17/2015	Steven R Hagen	SVP	Sell	1,000	$20.45	$20,450.00
6/10/2015	Ambra Constance M D	Major Shareholder	Sell	20,000	$19.77	$395,400.00
6/8/2015	Steven R Hagen	SVP	Sell	5,000	$19.99	$99,950.00
6/4/2015	William S Marth	CEO	Buy	10,000	$19.98	$199,800.00
6/1/2015	Stuart M Cable	Major Shareholder	Sell	30,000	$19.69	$590,700.00
5/11/2015	Ambra Constance M D	Major Shareholder	Sell	20,000	$19.11	$382,200.00
5/8/2015	Steven R Hagen	SVP	Sell	14,500	$19.27	$279,415.00
4/10/2015	Ambra Constance M D	Major Shareholder	Sell	20,000	$18.50	$370,000.00
3/17/2015	Steven R Hagen	SVP	Sell	3,500	$18.53	$64,855.00
3/12/2015	Kevin Oconnor	Director	Sell	5,000	$18.22	$91,100.00
3/10/2015	Ambra Thomas E Phd D	Director	Sell	20,000	$17.65	$353,000.00
3/10/2015	George Svokos	Insider	Buy	10,000	$17.72	$177,200.00
3/5/2015	William S Marth	CEO	Buy	20,000	$17.70	$354,000.00
3/2/2015	Stuart M Cable	Major Shareholder	Sell	30,000	$16.39	$491,700.00
2/10/2015	Ambra Thomas E Phd D	Director	Sell	20,000	$16.91	$338,200.00
2/2/2015	Stuart M Cable	Major Shareholder	Sell	30,000	$16.32	$489,600.00
1/12/2015	Ambra Thomas E Phd D	Director	Sell	20,000	$16.45	$329,000.00
1/7/2015	Stuart M Cable	Major Shareholder	Sell	7,694	$16.00	$123,104.00
1/5/2015	Stuart M Cable	Major Shareholder	Sell	22,306	$16.21	$361,580.26
12/10/2014	Ambra Constance M D	Major Shareholder	Sell	20,000	$16.24	$324,800.00
12/5/2014	Stuart M Cable	Major Shareholder	Sell	13,307	$16.00	$212,912.00
12/4/2014	Stuart M Cable	Major Shareholder	Sell	16,693	$16.00	$267,088.00
11/10/2014	William S Marth	CEO	Buy	30,000	$17.01	$510,300.00
10/10/2014	Ambra Constance M D	Major Shareholder	Sell	20,000	$21.62	$432,400.00
10/1/2014	Lori M Henderson	SVP	Sell	1,000	$21.48	$21,480.00
10/1/2014	Stuart M Cable	Major Shareholder	Sell	30,000	$21.61	$648,300.00
9/10/2014	Ambra Constance M D	Major Shareholder	Sell	20,000	$20.12	$402,400.00
9/2/2014	Lori M Henderson	SVP	Sell	2,500	$19.56	$48,900.00
8/28/2014	Steven R Hagen	SVP	Sell	1,250	$19.74	$24,675.00
8/14/2014	Michael M Nolan	CFO	Sell	10,000	$19.76	$197,600.00
8/12/2014	Lori M Henderson	SVP	Sell	30,000	$19.05	$571,500.00
8/11/2014	Ambra Thomas E Phd D	Director	Sell	20,000	$18.99	$379,800.00
8/8/2014	Steven R Hagen	SVP	Sell	10,797	$18.99	$205,035.03
8/1/2014	Lori M Henderson	SVP	Sell	2,500	$18.56	$46,400.00
8/1/2014	Stuart M Cable	Major Shareholder	Sell	30,000	$18.69	$560,700.00
7/10/2014	Ambra Thomas E Phd D	Director	Sell	20,000	$20.94	$418,800.00
7/1/2014	Lori M Henderson	SVP	Sell	2,500	$20.62	$51,550.00
7/1/2014	Stuart M Cable	Major Shareholder	Sell	30,000	$21.00	$630,000.00
6/3/2014	Steven R Hagen	SVP	Sell	2,500	$16.93	$42,325.00
5/16/2014	Steven Hagen	SVP	Sell	1,250	$15.45	$19,312.50
5/15/2014	George Svokos	SVP	Buy	10,000	$15.60	$156,000.00
5/12/2014	Steven Hagen	SVP	Sell	5,897	$15.00	$88,455.00
5/12/2014	William Marth	CEO	Buy	30,000	$15.40	$462,000.00
5/1/2014	Lori Henderson	VP	Sell	2,500	$15.73	$39,325.00
5/1/2014	Stuart Cable	major shareholder	Sell	30,000	$15.98	$479,400.00
4/1/2014	Lori Henderson	VP	Sell	2,500	$18.74	$46,850.00
4/1/2014	Stuart Cable	major shareholder	Sell	30,000	$18.52	$555,600.00
2/27/2014	Arthur Roth	Director	Sell	5,000	$15.95	$79,750.00
2/27/2014	Steven Hagen	SVP	Sell	3,000	$15.73	$47,190.00
2/25/2014	Steven Hagen	SVP	Sell	2,500	$15.19	$37,975.00
2/24/2014	Michael Nolan	CFO	Sell	15,000	$15.00	$225,000.00
2/21/2014	Steven Hagen	SVP	Sell	1,500	$14.87	$22,305.00
2/19/2014	Steven Hagen	SVP	Sell	1,500	$13.37	$20,055.00
2/13/2014	Stuart Cable	major shareholder	Sell	30,000	$12.00	$360,000.00
12/4/2013	Steven Hagen	SVP	Sell	2,500	$10.93	$27,325.00
12/3/2013	William Marth	Director	Buy	30,000	$10.75	$322,500.00
11/22/2013	Steven Hagen	SVP	Sell	2,300	$11.55	$26,565.00
11/22/2013	William Marth	Director	Buy	20,000	$11.57	$231,400.00
9/13/2013	Stuart Cable	major shareholder	Sell	30,000	$12.00	$360,000.00
8/1/2013	Stuart M Cable	Major Shareholder	Sell	30,000	$12.53	$375,900.00
7/1/2013	Stuart M Cable	Major Shareholder	Sell	30,000	$12.47	$374,100.00
6/12/2013	Stuart M Cable	Major Shareholder	Sell	30,000	$12.00	$360,000.00
5/22/2013	Bruce J Sargent	SVP	Sell	7,500	$10.97	$82,275.00
5/10/2013	Steven R Hagen	SVP	Sell	1,200	$10.40	$12,480.00
12/3/2012	William S Marth	Director	Buy	10,000	$5.00	$50,000.00
11/15/2012	Ambra Thomas E Phd D	CEO	Buy	10,000	$3.80	$38,000.00
8/9/2012	Steven R Hagen	VP	Sell	3,000	$3.00	$9,000.00

(Data available from 1/1/2013 forward)

Latest Headlines for Albany Molecular Research (NASDAQ:AMRI)

Date	Headline
	Albany Molecular Research, Inc. (NASDAQ:AMRI) under Investigation for Long-Term Investors (NASDAQ:AMRI) www.openpr.com - September 29 at 3:42 PM
	ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets, Financial Sta (NASDAQ:AMRI) biz.yahoo.com - September 24 at 8:48 AM
	Albany Molecular Research, Inc. – Value Analysis (NASDAQ:AMRI) : September 15, 2016 (NASDAQ:AMRI) www.capitalcube.com - September 15 at 12:23 PM
	Albany Molecular Research, Inc. breached its 50 day moving average in a Bearish Manner : AMRI-US : September 14, 2016 (NASDAQ:AMRI) www.capitalcube.com - September 14 at 3:30 PM
	Investor News: Investigation over possible Misconduct at Albany Molecular Research, Inc. (NASDAQ:AMRI) (NASDAQ:AMRI) www.groundreport.com - September 13 at 8:20 AM
	Scienter and Securities Law; Federal Tort Claims Act; Tax Prosecution (NASDAQ:AMRI) www.newyorklawjournal.com - September 8 at 3:28 PM
	Investigation for Long-Term Investors in Albany Molecular Research, Inc. (NASDAQ:AMRI) Announced (NASDAQ:AMRI) www.4-traders.com - August 30 at 11:29 AM
	AMRI CEO to Present at Morgan Stanley Global Healthcare Conference (NASDAQ:AMRI) finance.yahoo.com - August 30 at 11:29 AM
	BRIEF-Albany Molecular Research announces restructuring plan of certain operations in U.S.and Europe (NASDAQ:AMRI) www.reuters.com - August 29 at 9:08 PM
	Albany Molecular Research (AMRI) Announces Euticals Acquisition-Related Restructuring Plan (NASDAQ:AMRI) www.streetinsider.com - August 29 at 9:08 PM
	ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Material Impairm (NASDAQ:AMRI) biz.yahoo.com - August 29 at 9:08 PM
	Albany Molecular Research licenses CRISPR-Cas9 gene editing technology (NASDAQ:AMRI) www.pharmabiz.com - August 27 at 8:18 AM
	Albany Molecular Research : AMRI CEO TO PRESENT AT BAIRD 2016 GLOBAL HEALTHCARE CONFERENCE (NASDAQ:AMRI) www.4-traders.com - August 27 at 8:18 AM
	ETF’s with exposure to Albany Molecular Research, Inc. : August 26, 2016 (NASDAQ:AMRI) www.capitalcube.com - August 26 at 11:37 AM
	Albany Molecular Research : AMRI LICENSES CRISPR-CAS9 GENE EDITING TECHNOLOGY (NASDAQ:AMRI) www.4-traders.com - August 25 at 3:31 PM
	Albany Molecular Research : Update in Lawsuit for Investors in Albany Molecular Research, Inc. shares announced by Shareholders Foundation (NASDAQ:AMRI) www.4-traders.com - August 25 at 8:18 AM
	Albany Molecular Research, Inc. breached its 50 day moving average in a Bearish Manner : AMRI-US : August 25, 2016 (NASDAQ:AMRI) www.capitalcube.com - August 25 at 8:18 AM
	Drug Discovery Informatics Market size to exceed USD 6.5 billion by 2023 (NASDAQ:AMRI) reports.pr-inside.com - August 24 at 3:31 PM
	AMRI : CEO to Present at Baird 2016 Global Healthcare Conference (NASDAQ:AMRI) www.4-traders.com - August 24 at 3:31 PM
	AMRI CEO to Present at Baird 2016 Global Healthcare Conference (NASDAQ:AMRI) finance.yahoo.com - August 24 at 11:45 AM
	AMRI : Licenses CRISPR-Cas9 Gene Editing Technology (NASDAQ:AMRI) www.4-traders.com - August 23 at 8:46 PM
	BRIEF-Albany Molecular Research enters into non-exclusive commercial license agreement with broad institute of MIT and Harvard (NASDAQ:AMRI) www.reuters.com - August 23 at 8:46 PM
	AMRI Licenses CRISPR-Cas9 Gene Editing Technology (NASDAQ:AMRI) finance.yahoo.com - August 23 at 8:46 PM
	4:06 pm Albany Molecular enters into a non-exclusive commercial license agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology, financial terms were not disclosed (NASDAQ:AMRI) finance.yahoo.com - August 23 at 8:46 PM
	Update in Lawsuit for Investors in Albany Molecular Research, Inc. shares announced by Shareholders Foundation (NASDAQ:AMRI) finance.yahoo.com - August 23 at 3:30 PM
	Update in Lawsuit for Investors in Albany Molecular Research, Inc. shares announced by Shareholders Foundation (NASDAQ:AMRI) finance.yahoo.com - August 23 at 3:30 PM
	Ryan & Maniskas, LLP Announces Investigation of Albany Molecular Research Inc. (NASDAQ:AMRI) finance.yahoo.com - August 10 at 9:56 PM
	Albany Molecular Research, Inc. :AMRI-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:AMRI) www.capitalcube.com - August 10 at 3:50 PM
	SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Albany Molecular Research, Inc. (AMRI) (NASDAQ:AMRI) finance.yahoo.com - August 9 at 12:15 PM
	Robbins Arroyo LLP Is Investigating the Officers and Directors of Albany Molecular Research, Inc. (AMRI) on Behalf of Shareholders (NASDAQ:AMRI) finance.yahoo.com - August 8 at 3:32 PM
	Edited Transcript of AMRI earnings conference call or presentation 4-Aug-16 12:30pm GMT (NASDAQ:AMRI) finance.yahoo.com - August 4 at 9:13 PM
	Albany Molecular Research Inc Earnings Call (Q2 2016) (NASDAQ:AMRI) biz.yahoo.com - August 4 at 3:33 PM
	AMRI – Albany Molecular Research Inc.: AMRI Announces Second Quarter 2016 Results (NASDAQ:AMRI) www.twst.com - August 4 at 3:33 PM
	Albany Molecular Research, Inc.'s (AMRI) CEO William Marth on Q2 2016 Results - Earnings Call Transcript (NASDAQ:AMRI) seekingalpha.com - August 4 at 3:33 PM
	Albany Molecular Research posts 2Q loss (NASDAQ:AMRI) finance.yahoo.com - August 4 at 3:33 PM
	SHAREHOLDER ALERT: Schubert Firm Announces Investigation into Possible Breaches of Fiduciary Duty by Albany Molecular Research Inc. Officers and Directors (NASDAQ:AMRI) finance.yahoo.com - July 28 at 8:00 AM
	Albany Molecular Research, Inc. breached its 50 day moving average in a Bearish Manner : AMRI-US : July 26, 2016 (NASDAQ:AMRI) www.capitalcube.com - July 26 at 8:13 AM
	Albany Molecular Research, Inc. – Value Analysis (NASDAQ:AMRI) : July 18, 2016 (NASDAQ:AMRI) www.capitalcube.com - July 18 at 3:31 PM
	AMRI to Announce Second Quarter 2016 Results (NASDAQ:AMRI) www.prnewswire.com - July 15 at 2:05 PM
	ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Creation of a D (NASDAQ:AMRI) biz.yahoo.com - July 12 at 5:11 PM
	Albany Molecular Research, Inc. breached its 50 day moving average in a Bullish Manner : AMRI-US : July 11, 2016 (NASDAQ:AMRI) www.capitalcube.com - July 11 at 8:32 AM
	AMRI Completes Acquisition of Euticals (NASDAQ:AMRI) www.publicnow.com - July 11 at 7:43 AM
	Teewinot Life Sciences Corporation Licenses Biosynthetic Technology to AMRI for the Production and Sale of the First Commercially Available CBCA Analytical Standard (NASDAQ:AMRI) finance.yahoo.com - June 22 at 8:00 AM
	AMRI Selected as a Dedicated Chemical Biology Consortium Center to Expand Drug Development (NASDAQ:AMRI) finance.yahoo.com - June 14 at 8:05 AM
	Albany Molecular Research, Inc. breached its 50 day moving average in a Bearish Manner : AMRI-US : June 13, 2016 (NASDAQ:AMRI) www.capitalcube.com - June 13 at 8:17 AM
	Drug Discovery Informatics Market size is anticipated to reach around USD 6.5 billion by 2023 (NASDAQ:AMRI) www.newsmaker.com.au - June 9 at 9:24 PM
	ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to (NASDAQ:AMRI) biz.yahoo.com - June 3 at 4:32 PM
	Albany Molecular Research, Inc. breached its 50 day moving average in a Bullish Manner : AMRI-US : June 2, 2016 (NASDAQ:AMRI) www.capitalcube.com - June 2 at 8:05 AM
	Albany Molecular Research, Inc. (AMRI) Given Buy Rating at Morgan Stanley - Let Me Know About This (NASDAQ:AMRI) www.lmkat.com - May 30 at 12:28 PM
	Albany Molecular Research, Inc. (NASDAQ:AMRI) Current Deferred Tax Assets At $3.586 Millions - RealistInvestor.com (NASDAQ:AMRI) www.realistinvestor.com - May 29 at 11:39 AM